Proteomics can help to define and identify patients that will most benefit from the increasing number of molecular-targeted agents. In particular, reverse phase protein microarray provides detailed information about the state of the cellular 'circuitry' from small samples such as patient biopsy specimens. This review discusses the clinical applications of this emerging technology and how it could be used to help guide individualized treatment approaches.
- Julia D Wulfkuhle
- Kirsten H Edmiston
- Emanuel F Petricoin III